This study aims to investigate the mechanism of lncRNA MEG8 on NSCLC progression. The mRNA expressions of MEG8 and miR-107 were examined in tumor and adjacent normal tissues from patients with NSCLC by qRT-PCR. Lung epithelial BEAS-2B cells were transfected with MEG8 overexpression plasmid, and NSCLC A549 and H1299 cells were transfected with MEG8 or miR-107 overexpression/knockdown plasmid to detect the function of MEG8 or miR-107 on cell activity. The function of MEG8 and miR-107 on cell proliferation,...
Hyperammonemic encephalopathy represents a rare adverse effect of several chemotherapeutic agents, occurring in about 0.7% of patients treated with fluoropyrimidines, and it is independent from dihydropyrimidine dehydrogenase deficiency. Instead, its physiopathology is linked to the inhibition of Krebs cycle by fluoroacetate, leading to decreased ATP production, and to the inhibition of the urea cycle. Oxaliplatin seems to induce hyperammonemic encephalopathy in a similar way, acting on mitochondria....
This study suggested that the depth of vemurafenib addiction in resistant melanoma cells is positively correlated to the drug dosage, which might be underpinned by the ERK1/2-FRA-1 pathway and the related cytokines. (Source: Anti-Cancer Drugs)
We report the failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. A 76-year-old man was admitted to our hospital for evaluation of an elevated serum prostate specific antigen (PSA) level (191.10 ng/ml) in August 2011. He was diagnosed with T3aN0M1b prostate adenocarcinoma. A combined androgen blockade using luteinizing hormone-releasing hormone agonist (the 1-month depot of leuprorelin acetate) and...
This study investigated the activity of PdpaMn on glycolysis and its mechanism. PdpaMn was used to suppress FASN expression in tumor. Expression of ATP and lactic acid level was measured to investigate the glycolysis variance in cells and animals. MCF-7 and 4T1 cells were treated with G28UCM, an inhibitor of FASN and PdpaMn, western blotting to detect PI3K/Akt signaling pathway. The capacity of proliferation was investigated by western blotting and immunohistochemistry. PdpaMn selectively inhibits...
We report two cases of gastroenteropancreatic-NET patients receiving SSA lanreotide for the entire course of their pregnancy, with favorable outcomes for both mothers and babies. Our experience supports the possibility to continue safely SSA lanreotide during pregnancy in patients with NET. (Source: Anti-Cancer Drugs)
In this study, we investigated the effect of ticagrelor, a new antiplatelet drug, on tumor cell proliferation and metastasis. Our results show that ticagrelor not only inhibits the proliferation, migration, and invasion of B16F10 and Lewis lung carcinoma cells but also induces platelet apoptosis. In addition, we find that apoptosis of the platelet cells is dose dependent. Further, the result of in-vivo experiments proved that ticagrelor treatment decreased the tumor metastasis. The results of this...
Endometrial cancer is the commonest gynecological cancer, the majority is endometrioid type, diagnosed at an early stage with 69–88% 5-year survival. Low-grade endometrial cancers have low recurrence rates and often do not receive adjuvant therapy; however, a subset of these patients will have poor outcomes and would benefit from adjuvant treatment has been challenging. We evaluate the circulating cell-free DNA (ccfDNA) in a patient with low-risk endometrial cancer in order to identify the presence...
Anlotinib is a multi-target tyrosine kinase inhibitor developed independently in China. Its biological effects remain unclear in small-cell lung cancer (SCLC). The current study aimed to evaluate the effects of anlotinib in combination with irinotecan on H446 and H2227 SCLC cell lines and provide new treatment strategy for SCLC. Cell growth of two cell lines was inhibited by anlotinib, irinotecan and the combination in a dose-dependent manner. After 72 h incubation, the inhibition rate was greater...
To evaluate pharmacokinetic and safety profile of LifePearl microspheres loaded with irinotecan (LifePearl-IRI) in the treatment of liver-dominant, metastatic colorectal carcinoma (LM-CRC) by transarterial chemoembolization. In a prospective, multicentre pharmacokinetic study, 14 patients with LM-CRC progressing on at least one line of chemotherapy were treated with LifePearl-IRI. Six patients received unilobar treatment, treating one lobe per session with 100 mg of irinotecan every 2 weeks. Eight...
In conclusion, TTTY15 plays an oncogenic role in ESCC by targeting miR-337-3p/JAK2 axis. (Source: Anti-Cancer Drugs)
The role of induction chemotherapy in the multidisciplinary treatment of locally advanced, nonlaryngeal high-risk human papilloma virus (HPV)-negative head and neck squamous cells carcinoma (HNSCC) is uncertain in terms of overall survival (OS). The primary objective of this study was to identify possible predictive factors of survival and outcome in patients with HNSCC who were treated with induction chemotherapy. Fifty-nine patients with stage IVa/b HPV-negative non-laryngeal HNSCC (mostly originating...
X-inactive-specific transcript (XIST) is a 19 kb noncoding RNA which is oncogenic in many cancers including gastric cancer. It is reported that XIST contributes to gastric cancer cells resistant to cisplatin, but specific mechanisms governing this resistance remain unclear. We firstly examined the XIST level in gastric cancer cells and tumor specimens. We confirmed that XIST is overexpressed in gastric cancer cells and tumors, which further contributed to the poor prognosis of patients with gastric...
Bone metastasis is one of the common phenomena in the late stage of lung cancer. Inhibition of bone metastasis can improve the survival of lung cancer patients. However, the current drugs for the treatment of bone metastasis have shown little effect on overall survival. Therefore, there is an urgent necessity to identify novel drugs capable of preventing and treating bone metastasis of lung cancer. Our study determined that icaritin (ICT) can inhibit lung cancer-mediated osteoclastogenesis and induce...
Lung cancer always ranks first in the number of cancer deaths every year, accounting for 18.4% of total cancer deaths in 2018. Metastasis is the main cause of death in lung cancer patients. The identification of bioactive components of traditional Chinese medicine is very important for the development of novel reagents against non-small cell lung cancer (NSCLC). Rosthorin A has originated from Rabdosia rosthornii (Diels) Hara which excerpts from ‘Chinese materia medica’, and is known to have ‘clear...
This study suggested that thioridazine + loratadine + R848 combinatorial treatment may be effective in overcoming immune evasion by tumor cells, with promising therapeutic potential in CRC. (Source: Anti-Cancer Drugs)
Inflammatory myofibroblastic tumour (IMT) is a rare malignancy with limited responses to corticosteroids and chemotherapy. About half of cases have activating rearrangements in the ALK gene which could be targeted with ALK inhibitors. A 40-year-old man presented with a large right lung mass and nodal, trapezius and cerebral metastases. Biopsy confirmed IMT with TPM4-ALK fusion. He was treated with prednisolone without clinical benefit. He received the Trk/ROS1/ALK inhibitor entrectinib in a clinical...
Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast cancer is HER2 IHC 2+/FISH-positive. Unlike trastuzumab, it has not been studied whether the response to trastuzumab emtansine (T-DM1) differs according to HER2-positive status. We retrospectively identified and reviewed medical records of all patients with...
After the failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, some non-small cell lung cancer patients desire to receive switching with another EGFR-TKI (TKI-switching), although cytotoxic chemotherapy has been recommended as second-line therapy. It is unclear who should not receive TKI-switching in these patients. We retrospectively evaluated overall survival (OS) from the initiation of first EGFR-TKI (first-TKI) therapy in advanced lung adenocarcinoma...
Since the introduction of antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies (moAbs), the treatment of metastatic colorectal cancer (mCRC) has become crucially dependent on the mutation profile of the tumour over the last two decades. Recently, rechallenge strategy with cetuximab-based chemotherapy has demonstrated to be active in a subgroup of patients whose tumour maintained wild-type RAS and RAF status. In this setting, liquid biopsy may replace tissue sample for the identification...
To evaluate the predictive value of preoperative biochemical marker [platelet-to-lymphocyte ratio (PLR)] in patients with advanced hepatocellular cancer receiving transarterial chemoembolization (TACE) plus targeted molecular therapy (apatinib) treatment. Clinical records of 134 patients receiving the treatment of TACE + apatinib (TACE-A) and the treatment of TACE alone were compared in a single-center study. Time to progression (TTP) and overall survival (OS) were compared between TACE-A and TACE...
In the present study, to delve into the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with temozolomide (TMZ) on high-grade glioma cells and related mechanism, six cases of high-grade glioma cells from patient’s tumor tissues were cultured. 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide (MTT) assay was performed to detect cell proliferation and toxicity. Flow cytometry was performed to...
We describe a 42-year-old man with chronic kidney disease stage 4 who was diagnosed with a mediastinal germ cell tumor and metastases in lung and brain. Treatment with cisplatin-etoposide was considered essential for a chance of cure. In order to administer the full cisplatin dose, 4-hour hemodialysis sessions were performed after each cisplatin infusion. During treatment cycle 3, 4 and 5, total and unbound plasma platinum concentrations were measured. Trough concentrations and half-life were at...
The hypoxic microenvironment is commonly found in various solid tumors including pancreatic ductal adenocarcinoma (PDAC). Saururus chinensis is a medicinal Chinese herb widely used because of documented anti-inflammatory and anti-angiogenic properties. Sauchinone is special active lignin extracted from S. chinensis and its biological functions have been extensively explored. Recent studies have found that sauchinone could affect tumor initiation, metastasis and progression of some cancers. However,...
In conclusion, TMEM45A is an oncogenic gene in glioma. The proliferation, migration, and invasion of gliomas could be effectively impeded by inhibition of TMEM45A, and the cancer-promoting effect of TMEM45A on gliomas was involved with the NFκB pathway. (Source: Anti-Cancer Drugs)
In conclusion, our results demonstrate for the first time that miR-338-3p targets ADAM17 and blocks the development of hypopharyngeal carcinoma involving the wnt/β-catenin signaling pathway, which may be a new target for clinical intervention in human cancer. (Source: Anti-Cancer Drugs)
Nasopharyngeal carcinoma (NPC) is a malignant tumor which is commonly found in East Asia and Africa. The present clinical treatment of NPC is still mainly based on chemotherapeutics and is prone to drug resistance and adverse reactions. Shikonin has been demonstrated to play the antitumor effect in various cancers. However, the specific effects and related regulatory mechanism of Shikonin in NPC have not been clearly declared yet. Cell viability was valued through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium...
In this study, we found that the expression of vesicular acetylcholine transporter, a biomarker of vagus nerve, was associated with hepatocellular carcinoma patients’ clinicopathological characteristics by immunohistochemistry. Further, activation of muscarinic acetylcholine receptor 1 (M1R) promoted HepG2 and SMMC-7721 cells migration and invasion and epithelial-mesenchymal transition via PI3K/Akt pathway. Moreover, inhibition of M1R by antagonist or shRNA suppressed hepatocellular carcinoma cells...
Recent findings implied the significance of reactive oxygen species (ROS) as a part of tyrosine kinase inhibitors (TKIs) pharmacological activity. Evidences also suggested that toxic effects of TKIs were related to ROS production. The results regarding benefits of vitamin E usage alongside with prescribed TKIs therapy are ambiguous. We aimed to examine oxidative stress and antioxidative defense in human serum treated with four different TKIs and their possible interactions with hydrosoluble vitamin...
With unique advantages, the small-molecule anticancer drugs have recently gained growing attention. Particular strategies, exemplified by high-throughput screening, fragment-based drug discovery, virtual screening and knowledge-based design, have been developed to identify active compounds. However, such screens generally rely on sophisticated and expensive instrumentations. Herein, we developed a simple spheroids 3D culture system to enable direct screening of small molecules with reliable results....
We described two splice variants of heparanase from Spalax, Splice 7 and splice 36, both devoid of heparanase enzymatic activity. Splice 7 increases tumor growth, while splice 36 functions as a dominant negative to wild-type heparanase and decreases tumor growth and metastasis. Here, we describe two novel splice variants of Spalax heparanase, splice 67 and splice 612. These splice variants result in production of a shorter heparanase proteins that are similar to the wild-type native heparanase in...
Mark above section as read
Publication date: Available online 15 October 2020Source: Cancer CellAuthor(s): Oula Dagher, Tiffany R. King, Nils Wellhausen, Avery D. Posey (Source: Cancer Cell)
Publication date: Available online 13 October 2020Source: Cancer CellAuthor(s): Carolina Bernabé, Ana I. Velázquez, Coral Olazagasti, Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Enrique Soto Pérez de Celis, Narjust Duma (Source: Cancer Cell)
Publication date: Available online 1 October 2020Source: Cancer CellAuthor(s): Ziad Bakouny, Jessica E. Hawley, Toni K. Choueiri, Solange Peters, Brian I. Rini, Jeremy L. Warner, Corrie A. Painter (Source: Cancer Cell)
Publication date: 12 October 2020Source: Cancer Cell, Volume 38, Issue 4Author(s): Beatriz Salvador-Barbero, Mónica Alvarez-Fernández, Elisabet Zapatero-Solana, Aicha El Bakkali, María del Camino Menéndez, Pedro P. López-Casas, Tomas Di Domenico, Tao Xie, Todd VanArsdale, David J. Shields, Manuel Hidalgo, Marcos Malumbres (Source: Cancer Cell)
Publication date: 12 October 2020Source: Cancer Cell, Volume 38, Issue 4Author(s): Wei Wang, Jill M. Marinis, Allison M. Beal, Shivraj Savadkar, Yue Wu, Mohammed Khan, Pardeep S. Taunk, Nan Wu, Wenyu Su, Jingjing Wu, Aarif Ahsan, Emma Kurz, Ting Chen, Inedouye Yaboh, Fei Li, Johana Gutierrez, Brian Diskin, Mautin Hundeyin, Michael Reilly, John D. Lich (Source: Cancer Cell)
Publication date: Available online 10 October 2020Source: Cancer CellAuthor(s): Carlos Cordon-Cardo, Elisabet Pujadas, Ania Wajnberg, Robert Sebra, Gopi Patel, Adolfo Firpo-Betancourt, Mary Fowkes, Emilia Sordillo, Alberto Paniz-Mondolfi, Jill Gregory, Florian Krammer, Viviana Simon, Luis Isola, Patrick Soon-Shiong, Judith A. Aberg, Valentin Fuster, David L. Reich (Source: Cancer Cell)
Publication date: Available online 9 October 2020Source: Cancer CellAuthor(s): Melinda A. Pruis, Burhan Hussain, Marleen Bakker, Rogier A.S. Hoek, Jelle R. Miedema, Anne-Marie C. Dingemans, Marthe S. Paats (Source: Cancer Cell)
Publication date: Available online 8 October 2020Source: Cancer CellAuthor(s): Steve Mao (Source: Cancer Cell)
Publication date: Available online 8 October 2020Source: Cancer CellAuthor(s): Liz Salmi, Zhiyong J. Dong, Bertram Yuh, Jan Walker, Catherine M. DesRoches (Source: Cancer Cell)
Publication date: Available online 5 October 2020Source: Cancer CellAuthor(s): Annalisa Trama, Claudia Proto, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Olivier Michielin, Fabrice Barlesi, Anne-Marie C. Dingemans, Jan Van Meerbeeck, Vera Pancaldi, Julien Mazieres, Ross A. Soo, Natasha B. Leighl, Solange Peters, Heather Wakelee, Leora Horn, Matthew Hellmann, Selina K. Wong, Marina Chiara Garassino, Javier Baena (Source: Cancer Cell)
Publication date: Available online 5 October 2020Source: Cancer CellAuthor(s): Annalisa Trama, Claudia Proto, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Olivier Michielin, Fabrice Barlesi, Anne-Marie C. Dingemans, Jan Van Meerbeeck, Vera Pancaldi, Julien Mazieres, Ross A. Soo, Natasha B. Leighl, Solange Peters, Heather Wakelee, Leora Horn, Matthew Hellmann, Selina K. Wong, Marina Chiara Garassino, Javier Baena (Source: Cancer Cell)
Publication date: Available online 2 October 2020Source: Cancer CellAuthor(s): Casmir Turnquist, Bríd M. Ryan, Izumi Horikawa, Brent T. Harris, Curtis C. Harris (Source: Cancer Cell)
Publication date: Available online 2 October 2020Source: Cancer CellAuthor(s): Yu Fujiwara, Yasuyoshi Sato, Xiaofei Wang, Katsunori Oikado, Yoshinao Sato, Naoki Fukuda, Taisuke Enokida, Koichi Takeda, Daisuke Ohkushi, Brian Hayama, Yoko Egi, Yoshitaka Tokai, Yumi Yamada, Yuki Nakajima, Motoko Kubota, Satomi Haruki, Takako Shimizu, Yasuko Uchida, Kuniko Utsugi, Yoshinori Ito (Source: Cancer Cell)
Publication date: Available online 1 October 2020Source: Cancer CellAuthor(s): Floris Dammeijer, Mandy van Gulijk, Evalyn E. Mulder, Melanie Lukkes, Larissa Klaase, Thierry van den Bosch, Menno van Nimwegen, Sai Ping Lau, Kitty Latupeirissa, Sjoerd Schetters, Yvette van Kooyk, Louis Boon, Antien Moyaart, Yvonne M. Mueller, Peter D. Katsikis, Alexander M. Eggermont, Heleen Vroman, Ralph Stadhouders, Rudi Hendriks, Jan von der Thüsen (Source: Cancer Cell)
Publication date: Available online 1 October 2020Source: Cancer CellAuthor(s): Han Chen, Han Liang (Source: Cancer Cell)
Publication date: Available online 1 October 2020Source: Cancer CellAuthor(s): Ziad Bakouny, Jessica E. Hawley, Toni K. Choueiri, Solange Peters, Brian I. Rini, Jeremy L. Warner, Corrie A. Painter (Source: Cancer Cell)
Publication date: Available online 24 September 2020Source: Cancer CellAuthor(s): Jun Li, Hu Chen, Yumeng Wang, Mei-Ju May Chen, Han Liang (Source: Cancer Cell)
Publication date: Available online 24 September 2020Source: Cancer CellAuthor(s): D.J. Crichton, A. Alphan, C.I. Amos, K. Anton, L. Cinquini, M. Colbert, Z. Feng, A. Goel, S. Kelly, H. Kincaid, Y. Liu, S. Lombeyda, A. Mahabal, A. Mishra, C. Patriotis, S. Srivastava (Source: Cancer Cell)
Publication date: Available online 24 September 2020Source: Cancer CellAuthor(s): Susana Ros, Alan J. Wright, Paula D'Santos, De-en Hu, Richard L. Hesketh, Yaniv Lubling, Dimitra Georgopoulou, Giulia Lerda, Dominique-Laurent Couturier, Pedram Razavi, Rapahel Pelossof, Ankita S. Batra, Elizabeth Mannion, David Y. Lewis, Alistair Martin, Richard D. Baird, Mafalda Oliveira, Leonora W. de Boo, Sabine C. Linn, Maurizio Scaltriti (Source: Cancer Cell)
Publication date: Available online 24 September 2020Source: Cancer CellAuthor(s): Linara Gabitova-Cornell, Aizhan Surumbayeva, Suraj Peri, Janusz Franco-Barraza, Diana Restifo, Nicole Weitz, Charline Ogier, Aaron R. Goldman, Tiffiney R. Hartman, Ralph Francescone, Yinfei Tan, Emmanuelle Nicolas, Neelima Shah, Elizabeth A. Handorf, Kathy Q. Cai, Alana M. O'Reilly, Ido Sloma, Rachel Chiaverelli, Richard A. Moffitt, Vladimir Khazak (Source: Cancer Cell)
Publication date: Available online 24 September 2020Source: Cancer CellAuthor(s): Emma Allen-Vercoe, Bryan Coburn (Source: Cancer Cell)
Publication date: Available online 17 September 2020Source: Cancer CellAuthor(s): James DeGregori, Paul Pharoah, Peter Sasieni, Charles Swanton (Source: Cancer Cell)
Publication date: Available online 17 September 2020Source: Cancer CellAuthor(s): Adham S. Bear, Robert H. Vonderheide, Mark H. O'Hara (Source: Cancer Cell)
Publication date: Available online 17 September 2020Source: Cancer CellAuthor(s): Rui Dong, Ran Yang, Yong Zhan, Hua-Dong Lai, Chun-Jing Ye, Xiao-Ying Yao, Wen-Qin Luo, Xiao-Mu Cheng, Ju-Ju Miao, Jun-Feng Wang, Bai-Hui Liu, Xiang-Qi Liu, Lu-Lu Xie, Yi Li, Man Zhang, Lian Chen, Wei-Chen Song, Wei Qian, Wei-Qiang Gao, Yun-Hui Tang (Source: Cancer Cell)
Publication date: Available online 15 September 2020Source: Cancer CellAuthor(s): Lars F. Westblade, Gagandeep Brar, Laura C. Pinheiro, Demetrios Paidoussis, Mangala Rajan, Peter Martin, Parag Goyal, Jorge L. Sepulveda, Lisa Zhang, Gary George, Dakai Liu, Susan Whittier, Markus Plate, Catherine B. Small, Jacob H. Rand, Melissa M. Cushing, Thomas J. Walsh, Joseph Cooke, Monika M. Safford, Massimo Loda (Source: Cancer Cell)
Publication date: 14 September 2020Source: Cancer Cell, Volume 38, Issue 3Author(s): Iannis Aifantis, Benjamin G. Neel (Source: Cancer Cell)
Publication date: 14 September 2020Source: Cancer Cell, Volume 38, Issue 3Author(s): Olli Dufva, Petri Pölönen, Oscar Brück, Mikko A.I. Keränen, Jay Klievink, Juha Mehtonen, Jani Huuhtanen, Ashwini Kumar, Disha Malani, Sanna Siitonen, Matti Kankainen, Bishwa Ghimire, Jenni Lahtela, Pirkko Mattila, Markus Vähä-Koskela, Krister Wennerberg, Kirsi Granberg, Suvi-Katri Leivonen, Leo Meriranta, Caroline Heckman (Source: Cancer Cell)
Mark above section as read
Risk higher in first five years of follow - up for those treated with breast - conserving surgery alone (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Prevalence of pancreatic cancer higher in patients with predisposing diabetes and obesity without BS (Source: The Doctors Lounge - Oncology)
Five - year survival for distant - stage prostate cancer improved from 2011 to 2016 (Source: The Doctors Lounge - Oncology)
Standalone D - dimer testing followed by whole - leg compression US in positive patients rules out DVT (Source: The Doctors Lounge - Oncology)
Higher CAC score calculated from radiotherapy - planning CT scan linked to increased risk for CVD (Source: The Doctors Lounge - Oncology)
The supplements contain cesium chloride, but no cesium chloride - containing products are FDA - approved (Source: The Doctors Lounge - Oncology)
Black, Hispanic patients with cancer significantly less likely to use video telehealth versus White patients (Source: The Doctors Lounge - Oncology)
Antifibrinolytic agent may lower 30 - day mortality when used within one hour of injury, for severe shock (Source: The Doctors Lounge - Oncology)
Despite progress, African Americans continue to have highest overall cancer death rate in the U.S. (Source: The Doctors Lounge - Oncology)
Participation rates similar for Black and White patients, treatment and cancer control trials (Source: The Doctors Lounge - Oncology)
Out - of - network claims involved anesthesiologist, pathologist in 64, 40 percent of cases, respectively (Source: The Doctors Lounge - Oncology)
Pulmonary complication, postoperative SARS - CoV - 2 infection rates lower with COVID - 19 - free pathways (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Poor outcomes include lower response rate to chemotherapy, higher mortality, recurrence (Source: The Doctors Lounge - Oncology)
Fertility maintained for women undergoing fertility - sparing surgery for borderline tumors (Source: The Doctors Lounge - Oncology)
Significant improvements seen in rates of invasive disease - free survival, distant recurrence - free survival (Source: The Doctors Lounge - Oncology)
Opdivo - Yervoy combination approved to treat adults with unresectable malignant pleural mesothelioma (Source: The Doctors Lounge - Oncology)
Authors caution that daily low - dose aspirin is linked to more late - stage cancers, related deaths in elderly (Source: The Doctors Lounge - Oncology)
Event - free survival not improved with use of adjuvant versus early salvage radiotherapy (Source: The Doctors Lounge - Oncology)
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib (Source: The Doctors Lounge - Oncology)
Risk for dying from breast cancer remains elevated 15 years after initial diagnosis (Source: The Doctors Lounge - Oncology)
Incidence rate ratio 0.12 among women vaccinated before age 17; 0.47 for those vaccinated at ages 17 to 30 (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Incidence up with frequent alcohol or meat consumption; no evidence of protective effect found for tea, coffee (Source: The Doctors Lounge - Oncology)
Counties with persistent poverty have higher overall, several type - specific cancer mortality rates (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Highest 30 - day mortality seen with cancer treatment one to three months before COVID - 19 diagnosis (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Findings seen in patients with advanced, metastatic disease that did not progress with first - line chemo (Source: The Doctors Lounge - Oncology)
57 percent of patients receiving active treatment had at least one change in treatment plans (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer (Source: The Doctors Lounge - Oncology)
(Source: The Doctors Lounge - Oncology)
Drug can be used for alopecia treatment in breast cancer survivors (Source: The Doctors Lounge - Oncology)
Less than one - third of doctors correctly agree that nicotine directly contributed to birth defects (Source: The Doctors Lounge - Oncology)
Risk for death significantly lower versus placebo in nonmetastatic, castration - resistant prostate cancer (Source: The Doctors Lounge - Oncology)
Mark above section as read
Nature Reviews Clinical Oncology, Published online: 16 October 2020; doi:10.1038/s41571-020-00443-3Salvage radiotherapy: a new standard of care
Nature Reviews Clinical Oncology, Published online: 15 October 2020; doi:10.1038/s41571-020-00441-5The coronavirus disease 2019 (COVID-19) pandemic has disrupted health care worldwide. Patients with cancer seem to be particularly susceptible to morbidities and mortality from this novel disease. No COVID-19-specific therapy currently seems to offer a survival benefit to this unique patient population. Furthermore, the global effects on routine cancer care will likely be felt for decades to come.
Mark above section as read
Taking the pre-reqs and reading papers that are more basic science focused (especially oncology related) I'm realizing i'm much more interested in the clinical side of medicine (outcomes, quality improvement, policy) and taking care of patients than I am in knowing the nitty gritty of basic science. Will I struggle in medical school? Is this still the right career path for me? (Source: Student Doctor Network)MedWorm Message: Have you tried our new medical search engine? More powerful than before....
What are my chances? Hometown (and currently living): Miami, FL Demographics: Caribbean/West Indian Male Graduated from University of Miami in May 2020 -Major: Neuroscience -Minors: Chemistry, Math, and Computer Science -Completed PRISM program (advanced science premed/research program) cGPA: 4.0 sGPA: 4.0 MCAT: 523 (129/131/132/131) LizzyM: 81 Research: Neuroscience lab (~400 hours) and biochemical breast cancer lab (~600 hours). Breast cancer research was clinically...
Everyone's favorite Vinay Prasad just posted this on Twitter: Here's the link to the article: LINK For those who saw the thread on Twitter, he's talking about HemeOnc/Fellowships in Medicine in general, but a few of the regular anonymous RadOnc Twitter accounts joined in. There are 8 points he makes in the article on why extra fellowships are a problem - I... Reform or Boycott Extra Fellowships (from Twitter) (Source: Student...
Mark above section as read
Date: Tuesday, 10 20, 2020; Speaker: Joyce Thompson , Postdoc, NICHD; Xiyuan Zhang, Postdoc, NCI; Ramiro Iglesias-Bartolome, Investigator, NCI; Zoom (Source: NIH Calendar of Events)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Date: Monday, 11 16, 2020; Speaker: See agenda for full list of speakers, https://events.cancer.gov/egrp/cohortconsortium/agenda; https://events.cancer.gov/egrp/cohortconsortium (Source: NIH Calendar of Events)
Mark above section as read
The ongoing COVID-19 pandemic, with lockdowns in many countries and the resultant disruption in transport systems, has affected supply chains globally. Pharmaceutical manufacturing has been affected because of delays in availability of raw materials and active pharmaceutical ingredients. Some countries imposed new trade restrictions to secure production of pharmaceuticals for their own consumption. An additional factor that has affected two leading drug manufacturing countries—India and China—is...
Health care and politics are inextricably linked in the USA. Just as elections are influenced by patterns in social behaviours and the economy, health-care access and affordability are influenced by elections1 and ideological disagreements regarding the involvement of governments in health care.2 Historically, Democrats have focused on increased access to health insurance coverage and Republicans have advocated for smaller government and privatisation of health care. The Affordable Care Act was enacted...
Mark above section as read
Renal cell carcinoma (RCC) is the most common malignant kidney tumor and has a high incidence rate. Circular RNAs (circRNAs) are noncoding RNAs with widespread distribution and diverse cellular functions. They... (Source: Molecular Cancer)
An amendment to this paper has been published and can be accessed via the original article. (Source: Molecular Cancer)
The highly intra-tumoral heterogeneity and complex cell origination of prostate cancer greatly limits the utility of traditional bulk RNA sequencing in finding better biomarker for disease diagnosis and strati... (Source: Molecular Cancer)
Metabolic reprogramming, including enhanced biosynthesis of macromolecules, altered energy metabolism, and maintenance of redox homeostasis, is considered a hallmark of cancer, sustaining cancer cell growth. M... (Source: Molecular Cancer)
As a point of convergence for numerous oncogenic signaling pathways, signal transducer and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune response. STAT3 is broadly hyperac... (Source: Molecular Cancer)
An amendment to this paper has been published and can be accessed via the original article. (Source: Molecular Cancer)
Mark above section as read
Among the DNA tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma herpesvirus (KSHV), account for a considerable percentage of virus-associated cancers. Deregulation of transcription factors signaling pa... (Source: Infectious Agents and Cancer)
Accelerated global control of cervical cancer would require primary prevention with human papillomavirus (HPV) vaccination in addition to novel screening program strategies that are simple, inexpensive, and ef... (Source: Infectious Agents and Cancer)
We propose an economical cervical screening research and implementation strategy designed to take into account the typically slow natural history of cervical cancer and the severe but hopefully temporary impac... (Source: Infectious Agents and Cancer)
This study was performed to evaluate the significance of positive resection margins (RMs) with the loop electrosurgical excision procedure combined with cold coagulation (LEEP with CC) as a definitive treatmen... (Source: Infectious Agents and Cancer)
Prostatic male genital schistosomiasis and prostate cancer co-existence cases are uncommon however, some studies have indicated that schistosomiasis may trigger development of prostate cancer regardless of age... (Source: Infectious Agents and Cancer)
Screening of unvaccinated women remains essential to mitigate the high morbidity/mortality of cervical cancer. Here, we compared visual inspection with acetic acid (VIA), recommended by WHO as the most cost-ef... (Source: Infectious Agents and Cancer)
The rapid growth of 2019 novel coronavirus (COVID-19) outbreak in Wuhan, China, at the early December 2019. COVID-19 spread all over the word just a few months. The outbreak of COVID-19 infection poses major t... (Source: Infectious Agents and Cancer)
Hepatocellular carcinoma (HCC) is one of the cancers of highest incidence and mortality worldwide. The proliferation and invasion of tumor cells are the main reason for poor prognosis after HCC surgery. Long n... (Source: Infectious Agents and Cancer)
Mark above section as read
CONCLUSION: Workflow Box™ automatic contouring software, based on our new atlas provides reliable and clinically relevant organs at risk and breast contouring. The contours proposed by the software from the new atlas were better than those obtained with the previous atlas based on 95% isodoses obtained from old treatment plans. This software has therefore become more efficient, justifying its use in routine clinical practice for breast cancer contouring in patients treated in the lateral decubitus...
[Erratum to "Stereotaxic radiotherapy of primary extracranial tumors" [Cancer Radiother. 24 (2020) DOI:10.1016/j.canrad.2020.06.020]]. Cancer Radiother. 2020 Sep 28;: Authors: Lerouge D, Latorzeff I, Mirabel X, Dohan A, Mordant P, Barry De Longchamps N, Giraud P PMID: 33004297 [PubMed - as supplied by publisher] (Source: Cancer Radiotherapie)
CONCLUSION: This atlas will be helpful for the volume definition in our daily practice of breast irradiation in lateral position and can open perspectives to develop also atlases for other alternative techniques as treatment in prone position. PMID: 32981844 [PubMed - as supplied by publisher] (Source: Cancer Radiotherapie)
Mark above section as read
CONCLUSION: EGI on histological samples is associated with increased rates of HPV 16, multiple high risk-HPV infections and CIN2+ lesions. EGI positive subjects also had an increased CIN recurrence/persistence after treatment compared to controls. PMID: 33041069 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: LARVH showed significant noninferiority for PFS and OS versus TARH in early cervical cancer, suggesting the potential oncologic safety of LARVH. PMID: 33041070 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: Intraoperative visual detection of SLNs in patients with VSCC using ICG-99mTc-nanocolloid was superior compared to 99mTc-nanocolloid and blue dye. The rate of successful SLN procedures between both groups was not significantly different. Fluorescence imaging has potential to be used routinely in the SLN procedure in VSCC patients to facilitate the search by direct visualization. CLINICAL TRIAL REGISTRATION: Netherlands Trial Register (Trial ID NL7443). PMID: 33041071 [PubMed...
CONCLUSION: Maintenance letrozole is a cost-effective treatment strategy in patients with advanced LGSC resulting in clinically-relevant improvement in QALYs, LYs, and fewer disease recurrences. PMID: 33032821 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: BRIP1-deficient ovarian epithelial cells exhibit defective HR, resulting in synthetic lethality when exposed to a platinum agent/PARPi combination. PARPi alone had no effect; this lack of effect may result from distinguishing molecular properties of BRIP1and/or consequences of genomic background. Our study identifies altered BRIP1 as a target for precision medicine-based therapies for ovarian cancers. This investigation supports consideration of the use of a platinum agent/PARPi combination...
CONCLUSIONS: Our study supports the existence of clinically relevant marker- and localization defined macrophage subsets in HGSC, which are independently regulated. Moreover, it suggests stromal CD11c as a novel prognostic marker in HGSC. PMID: 33032823 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: LEEP was not associated with a greater likelihood of positive margins, specimen fragmentation or smaller excision compared to CKC when performed according to a standardized protocol. However, the study was not powered to establish non-inferiority of LEEP and a definitive phase 3 trial to compare margin status and rates of treatment failure after LEEP and CKC is warranted. PMID: 33032824 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: Although second-line therapy for resistant or relapsed low risk GTN is able to achieve complete remission in most cases, time to complete remission for relapsed disease was shorter than for resistant disease. Further studies on the biologic differences between resistant and relapsed disease may clarify the optimal treatment for these clinical situations. PMID: 33023756 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
CONCLUSION: Decreased SMI during neoadjuvant chemotherapy was not associated with worse outcome in patients with stage III ovarian cancer included in the OVHIPEC-trial. However, a strong association between decreasing SMI and adverse events was found. PMID: 33019981 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: This novel machine learning algorithm demonstrates improved prognostic prediction for patients with endometrial cancer. Using machine learning for endometrial cancer allows for the integration of multiple factors to develop a precision prognostication system. PMID: 33019982 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Authors: Gershenson DM, Cobb LP, Sun CC PMID: 33019983 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Authors: Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF Abstract Homologous recombination DNA repair deficiency (HRD) is a functional defect in homologous recombination DNA repair, arising from germline or somatic mutations in BRCA1/2 or other mechanisms. Cells with HRD are more sensitive to platinum and poly(ADP-ribose) polymerase inhibitors (PARPi). HRD generates permanent changes in the genome with specific, quantifiable patterns ("genomic scars"). Clinical tests for HRD,...
Authors: Rossi EC PMID: 33008583 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: A newly developed two-marker ROCA administered every 4 months had lower call-back rates than SOC surveillance. Having established high specificity, the two-marker ROCA score deserves further evaluation for sensitivity in a larger trial. PMID: 33012551 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Authors: Stenzel AE, Moysich KB, Ferrando CA, Starbuck KD Abstract Transgender men remain at risk for gynecologic malignancies, but are an underserved population. Members of the transgender community experience discrimination and have experiences that contribute to health disparities, including in gynecology and oncology. While efforts have been made within the United States to reduce inequalities experienced by members of this community, many needs in the clinical setting remain. Increased...
CONCLUSION: Chemoradiotherapy is associated with lower mortality compared to single modality therapy and has a similar risk of early and late term toxicities compared to CT, though higher risk of early toxicities compared to RT. PMID: 33008633 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Authors: Nasioudis D, Albright BB, Roy A, Ko EM, Giuntoli RL, Haggerty AF, Cory L, Kim SH, Morgan MA, Latif NA PMID: 33004215 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: The results confirm the dominant role of CA125 for identifying malignancy, and suggest that other markers (HE4, CA72.4, CA15.3 and LAP) may help to distinguish between stage I and stage II-IV malignancies. However, further research is needed, also to investigate the added value over clinical and ultrasound predictors of malignancy, focusing on the differentiation between subtypes of malignancy. PMID: 32994054 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Authors: Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT PMID: 32994055 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: In general, primary treatment of patients with vulvar squamous cell carcinoma in Sweden adhered to guidelines. Areas of improvement include treatment for stage II and for the very old. PMID: 32988623 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: Olaparib reduced expression of cyclin D1, which positively correlated with PARP-1 levels. This effect was more evident in ARID1A-deficient tumors. Olaparib further induced inhibition of GLUT1 plasma activity. Our findings could have noteworthy implications in predicting which patients with EC would benefit from olaparib-based strategies. PMID: 32988624 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: Dose-escalated IMRT for locally-advanced vulvar cancer is well tolerated, with rates of cCR and pCR that compare favorably with published data. PMID: 32981696 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: Together, these data demonstrate that WNT7B/FZD5-LGR4/ELF3 axis maintains HGSOC cell epithelial phenotype and stem-like traits; targeting this axis may prevent HGSOC metastasis. PMID: 32980127 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: These data demonstrate the importance of appropriate dose reduction according to toxicity criteria and support the safe long-term use of niraparib for maintenance treatment in patients with recurrent ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01847274. PMID: 32981695 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: More than one third of patients with gynecologic cancer at three affiliated New York City hospitals experienced a treatment delay, change or cancellation during the first two months of the COVID-19 pandemic. Among the three New York City boroughs represented in this study, likelihood of gynecologic oncology treatment modifications correlated with the case burden of COVID-19. PMID: 32981694 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: We identified significant disparities in the utilization of SLNB, as well as evidence that this less-invasive technique is associated with lower rates of certain perioperative complications. Equitable access to this emerging technique could lessen disparate outcomes. PMID: 32981697 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSIONS: This is the first study, suggesting the novel triazene drug CT913 as enhancer drug for extending the therapeutic spectrum of PARPi. PMID: 32980128 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
CONCLUSION: High-cost ovarian cancer admissions were three times more expensive than low-cost admissions. Fewer open and extended procedures with subsequently shorter lengths of stay may have contributed to decreasing inpatient costs over the study period. In this cohort of patients largely covered by Medicare, clinical factors outweigh socioeconomic factors as cost drivers. Understanding the relationship of disease-specific and social factors to cost will be important in informing future value-based...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου